Argenx
ARGX
#551
Rank
โ‚น3.090 T
Marketcap
โ‚น50,289
Share price
1.10%
Change (1 day)
51.93%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Revenue for Argenx (ARGX)

Revenue in 2024 (TTM): โ‚น184.58 Billion

According to Argenx 's latest financial reports the company's current revenue (TTM ) is โ‚น186.67 Billion. an increase over the revenue in the year 2023 that were of โ‚น102.08 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Argenx from 2013 to 2024

Annual revenue

Year Revenue Change
2024 โ‚น187.89 B84.05%
2023 โ‚น102.08 B200.36%
2022 โ‚น33.98 B
2019 โ‚น6.25 B206.83%
2018 โ‚น2.03 B-36.52%
2017 โ‚น3.20 B176.17%
2016 โ‚น1.16 B110.33%
2015 โ‚น0.55 B50.76%
2014 โ‚น0.36 B19.7%
2013 โ‚น0.30 B